135 related articles for article (PubMed ID: 24909539)
1. Contractile elements in muscular fascial tissue - implications for in-vitro contracture testing for malignant hyperthermia.
Hoppe K; Schleip R; Lehmann-Horn F; Jäger H; Klingler W
Anaesthesia; 2014 Sep; 69(9):1002-8. PubMed ID: 24909539
[TBL] [Abstract][Full Text] [Related]
2. In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced?
Metterlein T; Schuster F; Kranke P; Roewer N; Anetseder M
Eur J Anaesthesiol; 2011 Apr; 28(4):251-5. PubMed ID: 20827211
[TBL] [Abstract][Full Text] [Related]
3. Malignant hyperthermia in humans--standardization of contracture testing protocol.
Melton AT; Martucci RW; Kien ND; Gronert GA
Anesth Analg; 1989 Oct; 69(4):437-43. PubMed ID: 2782643
[TBL] [Abstract][Full Text] [Related]
4. Sevoflurane as a potential replacement for halothane in diagnostic testing for malignant hyperthermia susceptibility: results of a preliminary study.
Metterlein T; Hartung E; Schuster F; Roewer N; Anetseder M
Minerva Anestesiol; 2011 Aug; 77(8):768-73. PubMed ID: 21730923
[TBL] [Abstract][Full Text] [Related]
5. Porcine malignant hyperthermia: effects of temperature and extracellular calcium concentration on halothane-induced contracture of susceptible skeletal muscle.
Nelson TE; Bedell DM; Jones EW
Anesthesiology; 1975 Mar; 42(3):301-6. PubMed ID: 1115384
[TBL] [Abstract][Full Text] [Related]
6. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group.
Larach MG
Anesth Analg; 1989 Oct; 69(4):511-5. PubMed ID: 2675676
[No Abstract] [Full Text] [Related]
7. Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia.
Bendahan D; Guis S; Monnier N; Kozak-Ribbens G; Lunardi J; Ghattas B; Mattei JP; Cozzone PJ
Acta Anaesthesiol Scand; 2004 Sep; 48(8):1019-27. PubMed ID: 15315621
[TBL] [Abstract][Full Text] [Related]
8. Halothane-caffeine contracture testing in neuromuscular diseases.
Heiman-Patterson TD; Rosenberg H; Fletcher JE; Tahmoush AJ
Muscle Nerve; 1988 May; 11(5):453-7. PubMed ID: 3374516
[TBL] [Abstract][Full Text] [Related]
9. Fulminant malignant hyperthermia.
Bross T; Steinmann D
Acta Anaesthesiol Scand; 2008 Jan; 52(1):164-5. PubMed ID: 18173438
[No Abstract] [Full Text] [Related]
10. Malignant hyperthermia in China.
Xu ZH; Luo AL; Guo XY; Ren HZ; Wang YL; Zhang X; Huang YG; Ye TH
Anesth Analg; 2006 Oct; 103(4):983-5. PubMed ID: 17000816
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
[TBL] [Abstract][Full Text] [Related]
12. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders.
Hopkins PM; Ellis FR; Halsall PJ
Br J Anaesth; 1993 Apr; 70(4):397-401. PubMed ID: 8499197
[TBL] [Abstract][Full Text] [Related]
13. [In vitro caffeine test on skeletal muscle samples from swine].
Rösel U; Szentkuti L
Dtsch Tierarztl Wochenschr; 1993 Jan; 100(1):25-8. PubMed ID: 8428567
[TBL] [Abstract][Full Text] [Related]
14. Failure of the platelet-halothane nucleotide depletion test as a diagnostic or screening test for malignant hyperthermia.
Britt BA; Scott EA
Anesth Analg; 1986 Feb; 65(2):171-5. PubMed ID: 3942305
[TBL] [Abstract][Full Text] [Related]
15. The Israeli Diagnostic Center for Malignant Hyperthermia: 7-years' accumulated experience.
Glauber V; Ben Abraham R; Zweig A; Perel A
Isr J Med Sci; 1997 Oct; 33(10):643-7. PubMed ID: 9397136
[TBL] [Abstract][Full Text] [Related]
16. [Effect of chlorocresol vs caffeine on muscle contracture in malignant hyperthermia susceptible patients].
Ben-Abraham R; Krivosic-Horber RM; Haudcoeur G; Perel A; Adnet PJ
Harefuah; 1997 Jun; 132(12):839-41, 911. PubMed ID: 9264187
[TBL] [Abstract][Full Text] [Related]
17. Standards for halothane/caffeine contracture test.
Rosenberg H
Anesth Analg; 1989 Oct; 69(4):429-30. PubMed ID: 2782641
[No Abstract] [Full Text] [Related]
18. The in vitro determination of susceptibility to malignant hyperthermia.
Iaizzo PA; Lehmann-Horn F
Muscle Nerve; 1989 Mar; 12(3):184-90. PubMed ID: 2725548
[TBL] [Abstract][Full Text] [Related]
19. Muscle biopsy for malignant hyperthermia screening in children.
Ummenhofer W; Roesslein R; Sutter PM; Moser N; Kern C; Urwyler A
Eur J Pediatr Surg; 1997 Oct; 7(5):259-62. PubMed ID: 9402480
[TBL] [Abstract][Full Text] [Related]
20. Extending the skeletal muscle viability period in the malignant hyperthermia test.
Bina S; Holman S; Muldoon SM
Anesth Analg; 2003 Jan; 96(1):153-8, table of contents. PubMed ID: 12505942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
